While consensus was not reached for recontact of individuals with a GPV in intermediate penetrance CSGs (RAD51C and RAD51D) with respect to breast cancer risk management, consensus was reached for recontact for these genes (and BRIP1) with respect to ovarian cancer risk management. This evidence concerns the gene RAD51D and breast carcinoma.